Oral Chinese patent medicines in treatment of dysmenorrhea and clinical research status: a scoping review.
10.19540/j.cnki.cjcmm.20240925.501
- Author:
Xiao-Jun BU
1
;
Zhi-Ran LI
2
;
Wen-Ya WANG
3
;
Rui-Xue LIU
2
;
Jing-Yu REN
4
;
Lin XU
2
;
Xing LIAO
3
;
Wei-Wei SUN
2
Author Information
1. Graduate School of Beijing University of Chinese Medicine Beijing 100029, China Guang'anmen Hospital,China Academy of Chinese Medical Sciences Beijing 100053, China.
2. Guang'anmen Hospital,China Academy of Chinese Medical Sciences Beijing 100053, China.
3. Center for Evidence-based Chinese Medicine,Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
4. Community Health Service Center of Qingta Street,Fengtai District, Beijing 100141, China.
- Publication Type:English Abstract
- Keywords:
clinical research;
dysmenorrhea;
oral Chinese patent medicine;
rational use of medicine;
scoping review
- MeSH:
Dysmenorrhea/drug therapy*;
Humans;
Drugs, Chinese Herbal/administration & dosage*;
Female;
Administration, Oral;
Nonprescription Drugs/administration & dosage*
- From:
China Journal of Chinese Materia Medica
2025;50(3):787-797
- CountryChina
- Language:Chinese
-
Abstract:
A scoping review was performed to systematically search and summarize the clinical research in the treatment of dysmenorrhea with oral Chinese patent medicines. The oral Chinese patent medicines for treating dysmenorrhea in three major drug lists, guidelines, and textbooks were screened, and the relevant clinical trials were retrieved from eight Chinese and English databases. The key information of the included trials was extracted and visually analyzed. A total of 50 Chinese patent medicines were included, among which oral Chinese patent medicines for the dysmenorrhea patients with the syndrome of Qi stagnation and blood stasis accounted for the highest proportion, and the average daily cost varied greatly among Chinese patent medicines. A total of 150 articles were included, involving 22 Chinese patent medicines, among which Guizhi Fuling Capsules/Pills, Sanjie Zhentong Capsules, and Dan'e Fukang Soft Extract were the most frequently studied. These articles mainly reported randomized controlled trial(RCT), which mainly focused on the comparison of the intervention effect between Chinese patent medicines combined with western medicine and western medicine alone, and the sample size was generally 51-100 cases. The high-frequency outcome indicators belonged to nine domains such as effective rate, adverse reactions, and laboratory examinations. This study showed that oral Chinese patent medicines had advantages in the treatment of dysmenorrhea, and the annual number of related clinical trials showed an overall growing trend. However, there were still problems such as insufficient safety information and vague description of traditional Chinese medicine(TCM) syndromes types in the instructions of Chinese patent medicines. The available clinical research had shortcomings such as uneven distribution of Chinese patent medicines, limited research scale, poor methodological rigor, and insufficient standardization of outcome indicators. In the future, it is necessary to deepen the development of high-quality clinical research and improve the contents of the instructions to ensure the effectiveness and safety of the clinical application of oral Chinese patent medicines in the treatment of dysmenorrhea.
